A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (VIBRANT-HD)

A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study With Open-Label Extension to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of LMI070/Branaplam Administered as Weekly Oral Doses in Participants With Early Manifest Huntington's Disease

This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be efficacious over longer periods of time.

Study Overview

• Status: Completed
• Conditions: Early Manifest Huntington Disease
• Intervention / Treatment: Drug: Branaplam; Drug: Placebo

Detailed Description

This study is a randomized, double-blind, placebo-controlled study which will be conducted in approximately 75 early manifest HD participants.

After screening and baseline assessments are completed, participants will enter the Core Treatment Period which is double-blinded and placebo-controlled. The Core Treatment Period includes a Dose Range Finding (DRF) period of 17 weeks, followed by a Blinded Extension period of up to 53 weeks. Three cohorts will be enrolled in the Core Treatment Period, and data from each cohort will be evaluated for efficacy and safety before proceeding to a new cohort with a higher dose. The Core Treatment Period will serve to evaluate the safety, tolerability, pharmacokinetic(s) (PK) and pharmacodynamic(s) (PD) and to find the best dose(s) to use in future studies.

After the dose(s) is determined at the end of the Core Treatment Period, participants will roll over into the Open Label Extension (OLE) and will be given branaplam for approximately 1 year and attend clinic visits every 4 weeks. At the end of the OLE, the study may be amended to provide open-label branaplam beyond 1 year or a separate extension study may be initiated.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H2W 1T8
      • Novartis Investigative Site
• France
  • Angers Cedex 1, France, 49033
    • Novartis Investigative Site
  • Creteil, France, 94010
    • Novartis Investigative Site
  • Lille, France, 59037
    • Novartis Investigative Site
• Germany
  • Bochum, Germany, 44791
    • Novartis Investigative Site
  • Muenster, Germany, 48149
    • Novartis Investigative Site
  • Ulm, Germany, 89081
    • Novartis Investigative Site
• Hungary
  • Budapest, Hungary, 1085
    • Novartis Investigative Site
  • Szeged, Hungary, 6725
    • Novartis Investigative Site
• Spain
  • Barcelona, Spain, 08041
    • Novartis Investigative Site
  • Madrid, Spain, 28034
    • Novartis Investigative Site
  • Catalunya
    • Barcelona, Catalunya, Spain, 08036
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

• Signed informed consent must be obtained prior to participation in the study.
• Clinically diagnosed Stage 1 or 2 Huntington's disease with a diagnostic confidence level (DCL) = 4 and a United Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) >8 at screening.
• Genetically confirmed Huntington's disease, with presence of ≥40 cytosine-adenineguanine (CAG) repeats in the huntingtin gene.
• Male and female participants between 25 to 75 years of age, inclusive, on the day of Informed Consent signature.

Exclusion Criteria

• Prior participation in clinical trial investigating a huntingtin-lowering therapy (unless participant received only placebo).
• Participants taking medications prohibited by the protocol.
• Any medical history, lumbar surgery or condition that would interfere with the ability to complete the protocol specified assessments,
• Participant has other severe, acute or chronic medical conditions including unstable psychiatric conditions, or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of the study results.
• Any surgical or medical condition which might put the participant at risk in case of participation in the study. The Investigator should make this determination in consideration of the participant's medical history and/or clinical or laboratory evidence at the Screening visit:

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Arm A; Branaplam 56 mg oral solution once weekly	Drug: Branaplam; messenger ribonucleic acid (RNA) splicing modifier; Other Names: LMI070
Experimental: Treatment Arm B; Branaplam 112 mg oral solution once weekly	Drug: Branaplam; messenger ribonucleic acid (RNA) splicing modifier; Other Names: LMI070
Experimental: Treatment Arm C or X or Y; (C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly	Drug: Branaplam; messenger ribonucleic acid (RNA) splicing modifier; Other Names: LMI070
Placebo Comparator: Placebo; Matching placebo oral solution once weekly	Drug: Placebo; Matching placebo oral solution once weekly

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction (%) of mHTT protein in cerebrospinal fluid (CSF)	To assess the dose-response relationship of branaplam administered over 16 weeks on mHTT protein change from baseline in cerebrospinal fluid (CSF) obtained via lumbar puncture. Treatment is administered for 16 weeks and assessments are done over a 17 week period.	Baseline up to Week 17
Number of treatment emergent adverse events and serious adverse events	The occurrence of adverse events will be sought by non-directive questioning of the participant at each visit during the study. Adverse events also may be detected when volunteered by the participant during or between visits or through physical examination findings, laboratory test findings, or other assessments.	Baseline up to approximately 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Ventricular Volume, Caudate Volume and Total Brain Volume	Ventricular, Caudate and Total Brain Volume will be measured by structural magnetic resonance imaging (MRI)	Baseline up to approximately 2 years
Concentrations of total HTT and mHTT protein in CSF	The concentrations of total HTT and mHTT protein will be measured in CSF samples obtained via lumbar puncture	Baseline up to approximately 2 years
Change from baseline in the Unified Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC)	The TFC focuses on the Investigator's assessment of the participant's capacity to perform a range of activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.	Baseline up to approximately 2 years
Change from baseline in the Unified Huntington's Disease Rating Scale (UHDRS Total Motor Score (TMS)	The TMS is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. Scores range from 0 to 124; the higher score represents more significant impairment.	Baseline up to approximately 2 years
Change from baseline in the Unified Huntington's Disease Rating Scale (UHDRS) Independence Scale (IS)	The IS represents the Investigator's assessment of the participant's level of independence, including topics of employment, finances, self-care and feeding. The scale has 19 discrete scores, from 10 (tube fed, total bed care) to 100 (no special care needed) with 5 point increments in between.	Baseline up to approximately 2 years
Concentrations of total HTT and mHTT protein in plasma	The concentrations of total HTT and mHTT protein will be measured in plasma from blood samples.	Baseline up to approximately 2 years
Concentrations of total HTT and mHTT protein in peripheral blood mononuclear cells (PBMCs)	The concentrations of total HTT and mHTT protein will be measured in PBMCs from blood samples.	Baseline up to approximately 2 years
Area under the curve (AUC) of branaplam in plasma	AUC will be calculated by measuring concentrations of branaplam in blood samples	Baseline up to approximately 2 years
Maximum concentration (Cmax) of branaplam in plasma	Cmax of branaplam will be calculated by measuring concentration in blood samples	Baseline up to approximately 2 years
Time taken to reach Cmx (Tmax) of branaplam in plasma.	Tmax will be calculated by measuring concentrations of branaplam in blood samples	Baseline up to approximately 2 years
Drug concentration observed at the last planned timepoint prior to dosing (Ctrough) of branaplam in plasma	Ctrough will be calculated by measuring concentrations of branaplam in blood samples	Baseline up to approximately 2 years
Concentrations of branaplam in CSF	The concentration of branaplam will be measured in CSF samples collected via lumbar puncture	Baseline up to approximately 2 years
Concentration ratio of branaplam in CSF/plasma.	Concentration ratio will be calculated by measuring branaplam in CSF samples collected via lumbar puncture and blood samples	Baseline up to approximately 2 years
Area under the curve (AUC) of UFB112 in plasma	AUC will be calculated by measuring concentrations of UFB112 in blood samples	Baseline up to approximately 2 years
Maximum concentration (Cmax) of UFB112 in plasma	Cmax of UFB112 will be calculated by measuring concentration in blood samples	Baseline up to approximately 2 years
Time taken to reach Cmx (Tmax) of UFB112 in plasma.	Tmax will be calculated by measuring concentrations of UFB112 in blood samples	Baseline up to approximately 2 years
Drug concentration observed at the last planned timepoint prior to dosing (Ctrough) of UFB112 in plasma	Ctrough will be calculated by measuring concentrations of UFB112 in blood samples	Baseline up to approximately 2 years
Concentrations of UFB112 in CSF	The concentration of UFB112 will be measured in CSF samples collected via lumbar puncture	Baseline up to approximately 2 years
Concentration ratio of UFB112 in CSF/plasma.	Concentration ratio will be calculated by measuring UFB112 in CSF samples collected via lumbar puncture and blood samples	Baseline up to approximately 2 years

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): December 8, 2021
• Primary Completion (Actual): October 27, 2023
• Study Completion (Actual): October 27, 2023

Study Registration Dates

• First Submitted: October 15, 2021
• First Submitted That Met QC Criteria: October 27, 2021
• First Posted (Actual): November 8, 2021

Study Record Updates

• Last Update Posted (Estimated): February 6, 2024
• Last Update Submitted That Met QC Criteria: February 4, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; Adult; oral; HD; Huntington Disease; Early Manifest; Branaplam; LMI070; Dose Range Finding; mHTT
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Genetic Diseases, Inborn; Basal Ganglia Diseases; Movement Disorders; Neurodegenerative Diseases; Dyskinesias; Heredodegenerative Disorders, Nervous System; Dementia; Cognition Disorders; Chorea; Huntington Disease
• Other Study ID Numbers: CLMI070C12203

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No